Halozyme Therapeutics, Inc. (HALO) Shares Sold by NumerixS Investment Technologies Inc

Share on StockTwits

NumerixS Investment Technologies Inc cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 51.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 13,500 shares of the biopharmaceutical company’s stock after selling 14,500 shares during the quarter. NumerixS Investment Technologies Inc’s holdings in Halozyme Therapeutics were worth $230,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Artisan Partners Limited Partnership grew its position in shares of Halozyme Therapeutics by 0.7% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,709,020 shares of the biopharmaceutical company’s stock valued at $28,831,000 after purchasing an additional 11,260 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics by 76.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 643,822 shares of the biopharmaceutical company’s stock valued at $10,862,000 after purchasing an additional 277,953 shares during the period. BlackRock Inc. grew its position in shares of Halozyme Therapeutics by 5.7% in the 2nd quarter. BlackRock Inc. now owns 12,242,431 shares of the biopharmaceutical company’s stock valued at $206,530,000 after purchasing an additional 659,763 shares during the period. Spark Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $816,000. Finally, Schwab Charles Investment Management Inc. grew its position in shares of Halozyme Therapeutics by 7.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 999,260 shares of the biopharmaceutical company’s stock valued at $16,858,000 after purchasing an additional 72,392 shares during the period. Institutional investors and hedge funds own 83.88% of the company’s stock.

In other Halozyme Therapeutics news, major shareholder Randal J. Kirk sold 644,998 shares of the company’s stock in a transaction that occurred on Tuesday, August 28th. The stock was sold at an average price of $18.08, for a total transaction of $11,661,563.84. Following the completion of the transaction, the insider now owns 3,562,388 shares of the company’s stock, valued at approximately $64,407,975.04. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Randal J. Kirk sold 53,505 shares of the company’s stock in a transaction that occurred on Wednesday, June 27th. The stock was sold at an average price of $17.34, for a total value of $927,776.70. Following the transaction, the insider now directly owns 3,562,388 shares of the company’s stock, valued at approximately $61,771,807.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,278,021 shares of company stock valued at $74,892,770. Insiders own 16.80% of the company’s stock.

NASDAQ:HALO opened at $17.30 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $12.86 and a twelve month high of $21.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.49 and a quick ratio of 3.43. The company has a market cap of $2.58 billion, a price-to-earnings ratio of 34.38 and a beta of 1.93.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. Halozyme Therapeutics had a return on equity of 38.10% and a net margin of 23.88%. The firm had revenue of $35.20 million during the quarter, compared to the consensus estimate of $31.49 million. sell-side analysts forecast that Halozyme Therapeutics, Inc. will post -0.8 earnings per share for the current fiscal year.

HALO has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on Halozyme Therapeutics in a research report on Wednesday, August 22nd. They issued an “overweight” rating and a $27.00 price objective for the company. BMO Capital Markets boosted their price objective on Halozyme Therapeutics from $19.00 to $21.00 and gave the company a “market perform” rating in a research report on Wednesday, August 8th. ValuEngine upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Barclays lowered Halozyme Therapeutics from an “equal weight” rating to an “underweight” rating and set a $19.00 price objective for the company. in a research report on Friday, May 11th. Finally, TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c” rating in a research report on Tuesday, May 15th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Halozyme Therapeutics has an average rating of “Hold” and a consensus target price of $22.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Recommended Story: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply